Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing
Reexamination Certificate
2006-09-26
2006-09-26
Jones, Dameron L. (Department: 1618)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
C424S001110, C424S001650, C424S009200
Reexamination Certificate
active
07112319
ABSTRACT:
The present invention relates to devices and methods of use thereof for making semiderivative voltammetric and chronoamperometric measurements of chemicals, e.g. neurotransmitters, precursors, and metabolites, in vitro, in vivo, or in situ. The invention relates to methods of diagnosing and/or treating a subject as having or being at risk of developing a disease or condition that is associated with abnormal levels of one or more neurotransmitters including, inter alia, epilepsy, diseases of the basal ganglia, athetoid, dystonic diseases, neoplasms, Parkinson's disease, brain injuries, spinal cord injuries, and cancer. The invention provides methods of differentiating white matter from grey matter using microvoltammetry. In some embodiments, regions of the brain to be resected or targeted for pharmaceutical therapy are identified using Broderick probes. The invention further provides methods of measuring the neurotoxicity of a material by comparing Broderick probe microvoltammograms of a neural tissue in the presence and absence of the material.
REFERENCES:
patent: 4883057 (1989-11-01), Broderick
patent: 5353802 (1994-10-01), Ollmar
patent: 5443710 (1995-08-01), Broderick
patent: 5521101 (1996-05-01), Saini et al.
patent: 5569591 (1996-10-01), Kell et al.
patent: 5814991 (1998-09-01), Deimling
patent: 5938903 (1999-08-01), Broderick
patent: 6235489 (2001-05-01), Jackoawski
patent: 6287452 (2001-09-01), Allen et al.
patent: 6321101 (2001-11-01), Holmstrom
patent: 6321105 (2001-11-01), Jenkins et al.
patent: 6402689 (2002-06-01), Scarantino et al.
patent: 909143067 (1990-08-01), None
patent: 0487647 (1992-06-01), None
patent: 1007350 (1999-04-01), None
patent: 9102485 (1991-03-01), None
patent: WO 02/082970 (2002-10-01), None
Schuff N et al., 2002, “Selective reduction of N-acetylaspartate in medial temporal and parietal lobes in AD” Neurology 58(6):928-935.
Lim KO et al., 1999, “Compromised white matter tract integrity in schizophrenia inferred from diffusion tensor imaging” Arch Gen Psychiatry 56(4):367-374.
Lozano AM et al., 1995, “Microelectrode monitoring of cortical and subcortical structures during stereotactic surgery” Acta Neurochir Suppl (Wien) 64:30-34.
Noseworth JH et al., 1988, “Postnatal NMR changes in guinea pig central nervous system: potential relevance to experimental allergic encephalomyelitis” Magn Reson Med 6(2):199-211.
Kataoka K et al., 1987, “Differentiation between cortical and subcortical lesions following focal ischemia in cats by multimodality evoked potentials” J Neurol Sci 79(1-2):117-127.
Frytak S et al., 1985, “Magnetic resonance imaging for neurotoxicity in long-term survivors of carcinoma” Mayo Clin Proc 60(12):803-812.
Ohye C et al., 1984, “Stereotactic CT scan applied to stereotactic thalamotomy and biopsy” Act Neurochir (Wien) 71(1-2):55-68.
Patricia A. Broderick, Mar. 2002, “Microsensors Detect Neuroadaptation by Cocaine: Serotonin Release in Motor Basal Ganglia Is Not Rhythmic with Movement” in Handbook of Neurotoxicology, vol. 2 (Massaro EJ, ed.) Humanna Press, Totowa, NJ, Chapter 13, pp. 323-367.
Pacia S.V. Biogenic amines in the human neocortex in patients with neocortical Biogenic amines in the human neocortex in patients with neocortical and mesial temporal lobe epilepsy: identification with in situ microvoltammetry, Brain Res. Apr. 27, 2001;899(1-2):106-11.
Broderick, P.A., Pacia, S.V., Doyle, W.K. and Devinsky, O., 2000, Monoamine neurotransmitters in resected hippocampal subparcellations from neocortical and mesial temporal lobe epilepsy patients: in situ microvoltammetric studies. Brain Res. 878:48-63.
Broderick, P.A., 2000, Serotonin (5-HT) deficiency but high tryptophan (L-TP) concentrations within hippocampal subparcellations in patients with mesial temporal sclerosis (MTS). Amer. Epilepsy Soc. Los Angeles, CA, Epilepsia 41(Suppl.):91.
Morgan, P.T., Perrins, R., Lloyd, P.E. and Weiss, K.R., 2000, Intrinsic and extrinsic modulaton of a single central pattern generating circuit. J. Neurophysiol. 84:1186-1193.
Pearson, K. and Gordon, J., 2000, Locomotion, in Principles of Neural Science (Kandel, E.R., Schwartz, J.H. and Jessell, T.M., eds.), 4th edition, The McGraw Hill Companies, Inc., NY, pp. 738-755.
Allen, S.M. and Davis, W.M., 1999, Relationship of dopamine to serotonin in the neonatal 6-OHDA rat model of Lesch-Nyhan Syndrome. Behav. Pharmacol. 10:467-474.
Broderick, P.A., Jean-Baptiste, P., Vuong, A.V., Pacia, S.V., Doyle, W.K. and Devinsky, O., 1999, Neurochemical signals from living neocortex of Mesial Temporal Lobe Epilepsy (MTLE) patients studied by Broderick Probe® lauric acid and stearic acid miniature sensors. Epilepsia (Suppl.7) 40:78-79.
Stokes, A.H., Hastings, T.G., Vrana, K.E., 1999. Cytotoxic and Genototic Potential of Dopamine. J. Neurosci. Res. 55:659-665.
Arshawsky, Y.I., Deliagina, T.G., Orlovsky, G.N., Panchin, Y.V., Popova, L.B. and Sadreyev, R.I., 1998, Analysis of the central pattern generator for swimming in the mollusk, Clione. Ann. NY Acad. Sci. 860:51-69.
Bordey, A., Sontheimer, H., 1998. Properties of human glial cells associated with epileptic seizure foci. Epilepsy Res. 32:286-303.
Broderick, P.A. and Piercey, M.F., 1998, Clozapine, haloperidol, and the D4 antagonist, PNU-101387G: in vivo effects on mesocortical, mesolimbic, and nigrostriatal dopamine and serotonin release. J. Neural. Transm. 105:749-767.
Guertin, P.A. and Hounagaard, J., 1998, Chemical and electrical stimulation induce rhythmic motor activity in an in vitro preparation of the spinal cord from adult turtles. Neurosci. Lett. 245:5-8.
Katz, P.S., 1998, Neuromodulation intrinsic to the central pattern generator for escape swimming in Tritonia. Ann. NY Acad. Sci. 860:181-188.
Y. Kawaguchi and T. Shindou, 1998, Noradrenergic excitation and inhibition of GABAergic cell types in rat frontal cortex, J Neurosci 18:6963-6976.
Lucki, I., 1998, The spectrum of behaviors influenced by serotonin. Biol. Psychiat. 44:151-162.
Martin, P., 1998, 5-HT2 Receptor Antagonism and Antipsychotic Drugs; A Behavioral and Neurochemical Study in a Rodent Hypoglutamatergia Model. PhD. Thesis, Goteborg Univ., Sweden, pp. 1-64.
Sadamoto, H., Hatakeyama, D., Kojima, S., Fujito, Y. and Ito, E., 1998, Histochemical study on the relation between NO-generative neurons and central circuitry for feeding in the pond snail, Lymnaea Stagnalis. Neurosi. Res. 32:57-63.
Abi, Dargham, A., Laruelle, M., Aghajanian, G.K., Charney, D. and Krystal, J., 1997, The role of serotonin in the pathophysiology and treatment of schizophrenia. J. Neuropsychiat. Clin. Neurosci. 9:1-17.
Broderick et al., 1997, “A Four Week Follow-Up Study Of Serotonin (5-Ht) And Dopamine (Da) Release In Nucleus Accumbens Of Animals Behaving In An Open-Field Paradigm” Society for Neurosci Abstract 23:1867.
Broderick PA and FelixCF, 1997, “Serotonin (5-HT) Within Dopamine Reward Circuits Signals Open-field Behavior. II. Basis for 5-HT-DA Interaction in Cocaine Dysfunctional Behavior” Neuroscience and Biobehavioral Reviews 21(3):227-260.
W.K. Doyla and D.D. Spencer, Anterior temporal resections. In: Epilepsy: A comprehensive textbook. eds J Engel Jr. and TA Pedley. Lippincott-Raven Publishers, Philadelphia (1997) 1807-1815.
S.V. Pacia and J.S. Ebersole, 1997, Intracranial EEG substrates of Scalp ictal patterns from temporal lobe foci, Epilepsia 38:642-654.
Yeghiayan, S.K., Kelley, A.E., Kula, N.S., Campbell, A. and Baldessarini, R.J., 1997, Role of dopamine in behavioral effects of serotonin microinjected into rat striatum. Pharmacol. Biochem. Behav. 56:251-259.
Brooks DJ, 1996, Basal Ganglia function during normal and Parkinsonian movement, PET activation studies, In Advances in Neurology (Battistin, L. Scarlato, G., Caraceni, T. and Ruggieri, S. Eds.), Lippincott-Raven, Phil. PA. pp. 433-441.
Kapur, S. and Remington, G., 1996, Serotonin-dopamine interaction and its relevance to schizophrenia. Am. J. Psychiat. 153(4):466-476.
Kiehn, O. and Kjaerulff, O., 1996, Spatiotem
Broderick Patricia A.
Pacia Steven V.
Jones Dameron L.
Morgan & Finnegan , LLP
The Research Foundation of the City University of New York
LandOfFree
Identification, diagnosis, and treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Identification, diagnosis, and treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Identification, diagnosis, and treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3579919